149 related articles for article (PubMed ID: 35657056)
21. The effect of concomitant chemotherapy on parotid gland function following head and neck IMRT.
Miah AB; Gulliford SL; Bhide SA; Zaidi SH; Newbold KL; Harrington KJ; Nutting CM
Radiother Oncol; 2013 Mar; 106(3):346-51. PubMed ID: 23540553
[TBL] [Abstract][Full Text] [Related]
22. A study on the impact of patient-related parameters in the ability to spare parotid glands by intensity-modulated radiotherapy for head and neck squamous cell carcinomas.
Bandlamudi BP; Sharan K; Yathiraj PH; Singh A; Reddy A; Fernandes DJ; Srinivasa VM
J Cancer Res Ther; 2018; 14(6):1220-1224. PubMed ID: 30488833
[TBL] [Abstract][Full Text] [Related]
23. Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes.
Tam M; Riaz N; Kannarunimit D; Peña AP; Schupak KD; Gelblum DY; Wolden SL; Rao S; Lee NY
Am J Clin Oncol; 2015 Aug; 38(4):343-7. PubMed ID: 26208401
[TBL] [Abstract][Full Text] [Related]
24. Whole-Field Sequential Intensity-Modulated Radiotherapy for Local-Regional Advanced Head-and-Neck Squamous Cell Carcinoma.
Refaat T; Choi M; Thomas TO; Bacchus I; Agulnik M; Pelzer HJ; Mellott AL; Rademaker AW; Liu D; Sathiaseelan V; Mittal BB
Am J Clin Oncol; 2015 Dec; 38(6):588-94. PubMed ID: 24136140
[TBL] [Abstract][Full Text] [Related]
25. The role of the soft palate dose regarding normal tissue toxicities in older adults with head and neck cancer undergoing definitive radiotherapy.
Bitz HC; Sachpazidis I; Zou J; Schnell D; Baltas D; Grosu AL; Nicolay NH; Rühle A
Radiat Oncol; 2024 Apr; 19(1):53. PubMed ID: 38689338
[TBL] [Abstract][Full Text] [Related]
26. IMRT for head and neck cancer: reducing xerostomia and dysphagia.
Wang X; Eisbruch A
J Radiat Res; 2016 Aug; 57 Suppl 1(Suppl 1):i69-i75. PubMed ID: 27538846
[TBL] [Abstract][Full Text] [Related]
27. IMRT-SIB with concurrent and neo-adjuvant platinum-based chemotherapy for locally advanced head and neck squamous cell cancer: analysis of clinical outcomes in a retrospective series of a single institution.
Mazzeo E; Antognoni P; Parmiggiani M; D'Ambrosio C; De Marco G; Marra L; Gottardi G; Bertoni F
Tumori; 2014; 100(6):652-9. PubMed ID: 25688499
[TBL] [Abstract][Full Text] [Related]
28. Dose-response analysis of parotid gland function: what is the best measure of xerostomia?
Miah AB; Gulliford SL; Clark CH; Bhide SA; Zaidi SH; Newbold KL; Harrington KJ; Nutting CM
Radiother Oncol; 2013 Mar; 106(3):341-5. PubMed ID: 23566529
[TBL] [Abstract][Full Text] [Related]
29. NTCP modelling of xerostomia after radiotherapy for oropharyngeal cancer using the PRO-CTCAE and CTCAE scoring systems at different time-points post-RT.
Tzikas A; Lavdas E; Kehagias D; Amdur R; Mendenhall W; Sheets N; Green R; Chera B; Mavroidis P
Phys Med; 2023 Dec; 116():103169. PubMed ID: 37989042
[TBL] [Abstract][Full Text] [Related]
30. Using multivariate regression model with least absolute shrinkage and selection operator (LASSO) to predict the incidence of Xerostomia after intensity-modulated radiotherapy for head and neck cancer.
Lee TF; Chao PJ; Ting HM; Chang L; Huang YJ; Wu JM; Wang HY; Horng MF; Chang CM; Lan JH; Huang YY; Fang FM; Leung SW
PLoS One; 2014; 9(2):e89700. PubMed ID: 24586971
[TBL] [Abstract][Full Text] [Related]
31. SPECT/CT-guided elective nodal irradiation for head and neck cancer: Estimation of clinical benefits using NTCP models.
de Veij Mestdagh PD; Janssen T; Lamers E; Carbaat C; Hamming-Vrieze O; Vogel WV; Sonke JJ; Al-Mamgani A
Radiother Oncol; 2019 Jan; 130():18-24. PubMed ID: 30087057
[TBL] [Abstract][Full Text] [Related]
32. NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy.
Jakobi A; Stützer K; Bandurska-Luque A; Löck S; Haase R; Wack LJ; Mönnich D; Thorwarth D; Perez D; Lühr A; Zips D; Krause M; Baumann M; Perrin R; Richter C
Acta Oncol; 2015; 54(9):1658-64. PubMed ID: 26340301
[TBL] [Abstract][Full Text] [Related]
33. Design and Selection of Machine Learning Methods Using Radiomics and Dosiomics for Normal Tissue Complication Probability Modeling of Xerostomia.
Gabryś HS; Buettner F; Sterzing F; Hauswald H; Bangert M
Front Oncol; 2018; 8():35. PubMed ID: 29556480
[TBL] [Abstract][Full Text] [Related]
34. Combination of submandibular salivary gland transfer and intensity-modulated radiotherapy to reduce dryness of mouth (xerostomia) in patients with head and neck cancer.
Scrimger RA; Seikaly H; Vos LJ; Harris J; O'Connell D; Ghosh S; Debenham B; Jha N
Head Neck; 2018 Nov; 40(11):2353-2361. PubMed ID: 30175876
[TBL] [Abstract][Full Text] [Related]
35. Identification of Patient Benefit From Proton Therapy for Advanced Head and Neck Cancer Patients Based on Individual and Subgroup Normal Tissue Complication Probability Analysis.
Jakobi A; Bandurska-Luque A; Stützer K; Haase R; Löck S; Wack LJ; Mönnich D; Thorwarth D; Perez D; Lühr A; Zips D; Krause M; Baumann M; Perrin R; Richter C
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1165-1174. PubMed ID: 26194685
[TBL] [Abstract][Full Text] [Related]
36. A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma.
Saksø M; Andersen E; Bentzen J; Andersen M; Johansen J; Primdahl H; Overgaard J; Eriksen JG
Acta Oncol; 2019 Oct; 58(10):1495-1501. PubMed ID: 31519130
[No Abstract] [Full Text] [Related]
37. Parotid gland mean dose as a xerostomia predictor in low-dose domains.
Gabryś HS; Buettner F; Sterzing F; Hauswald H; Bangert M
Acta Oncol; 2017 Sep; 56(9):1197-1203. PubMed ID: 28502238
[TBL] [Abstract][Full Text] [Related]
38. Prediction of Radiation-Induced Parotid Gland-Related Xerostomia in Patients With Head and Neck Cancer: Regeneration-Weighted Dose.
van Rijn-Dekker MI; van Luijk P; Schuit E; van der Schaaf A; Langendijk JA; Steenbakkers RJHM
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):750-762. PubMed ID: 37150262
[TBL] [Abstract][Full Text] [Related]
39. Parotid gland fat related Magnetic Resonance image biomarkers improve prediction of late radiation-induced xerostomia.
van Dijk LV; Thor M; Steenbakkers RJHM; Apte A; Zhai TT; Borra R; Noordzij W; Estilo C; Lee N; Langendijk JA; Deasy JO; Sijtsema NM
Radiother Oncol; 2018 Sep; 128(3):459-466. PubMed ID: 29958772
[TBL] [Abstract][Full Text] [Related]
40. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
